CorMedix Inc.  

(Public, NYSEMKT:CRMD)   Watch this stock  
Find more results for CRMD
-0.10 (-5.00%)
After Hours: 2.62 +0.72 (37.89%)
Jun 28, 4:57PM EDT  
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.83 - 2.15
52 week 1.15 - 6.27
Open 2.04
Vol / Avg. 534,366.00/389,272.00
Mkt cap 72.06M
P/E     -
Div/yield     -
EPS -0.49
Shares 36.22M
Beta 0.46
Inst. own 22%
May 6, 2016
Q1 2016 CorMedix Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -10212.82% -8655.37%
Operating margin -10285.61% -7925.56%
EBITD margin - -7918.38%
Return on average assets -48.00% -86.20%
Return on average equity -52.60% -96.80%
Employees 9 -
CDP Score - -


1430 US Highway 206 Ste 200
BEDMINSTER, NJ 07921-4602
United States - Map
+1-908-5179500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Officers and directors

Cora M. Tellez Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Randy Milby Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
James Altland Interim Chief Financial Officer
Bio & Compensation  - Reuters
Antony E. Pfaffle M.D. Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Myron M. Kaplan Director
Age: 69
Bio & Compensation  - Reuters
Janet M. Dillione Independent Director
Age: 55
Bio & Compensation  - Reuters
Matthew P. Duffy Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael W. George Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven W. Lefkowitz Independent Director
Age: 59
Bio & Compensation  - Reuters